Bimekizumab for Hidradenitis Suppurativa: Pathophysiology and Promising Interventions.

IF 2.1 4区医学 Q3 DERMATOLOGY

Cutis Pub Date : 2025-01-01 DOI:10.12788/cutis.1154

Mohammad Fardos, Ameije Ismaili, Summer Moon

引用次数: 0

Abstract

Hidradenitis suppurativa (HS) is a debilitating dermatologic disorder characterized by recurrent inflammation that affects the apocrine glands and hair follicles and profoundly impacts patients' quality of life. Current treatment strategies ranging from topical therapies to systemic biologics aim to alleviate symptoms and prevent disease progression. Bimekizumab, an IL-17A and IL-17F inhibitor, has emerged as a promising intervention in the HS treatment landscape. We present a comprehensive review of the underlying molecular pathophysiology of HS, current standards of care, and evaluation of the efficacy and safety of bimekizumab.

查看原文本刊更多论文

比美珠单抗治疗化脓性汗腺炎：病理生理学和有希望的干预措施。

化脓性汗腺炎（HS）是一种使人衰弱的皮肤病，其特征是复发性炎症，影响大汗腺和毛囊，严重影响患者的生活质量。目前的治疗策略，从局部治疗到全身生物制剂，旨在缓解症状和预防疾病进展。Bimekizumab是一种IL-17A和IL-17F抑制剂，已成为一种有希望的HS治疗干预手段。我们全面回顾了HS的潜在分子病理生理学，目前的护理标准，以及比美珠单抗的疗效和安全性评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cutis 医学-皮肤病学

CiteScore

1.10

自引率

0.00%

发文量

191

审稿时长

6-12 weeks

期刊介绍： Published since 1965, Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner. The journal is published monthly and focuses on concise clinical articles that present the practical side of dermatology. Referenced in Index Medicus/MEDLINE, it is respected and enjoyed by both specialists and derm-active generalists, enabling its readers to get what they need quickly and efficiently. Furthermore, Cutis is read by more physicians actively involved in the day-to-day treatment of dermatologic conditions than any other dermatology publication. Covering a broad range of pertinent and timely topics, Cutis is written and edited by industry leaders. For information on article submissions, please see our Information for Authors.